FDA refuses to review Moderna’s application for mRNA flu vaccine – One America News Network

0
94
(Background) The Moderna, Inc. logo is displayed on January 5, 2023. (Photo by PATRICK T. FALLON/AFP via Getty Images) / (R) A vial of Comirnaty LP.8.1 mRNA Covid-19 vaccine sits on the counter on 19 December 2025. (Photo by Jean-François FORT / Hans Lucas / AFP via Getty Images)

OAN Staff Katherine Mosack
2:41 PM – Wednesday, February 11, 2026

Moderna announced that the U.S. Food and Drug Administration (FDA) has refused to consider its application for a new flu vaccine using mRNA technology.

On Tuesday, the company reported in a news release that it had received a Refusal-to-File (RTF) letter from the FDA for its Investigational Seasonal Influenza Vaccine, mRNA-1010, despite filing a Priority Review Voucher to “facilitate a timely review of the application.”

The RTF letter, signed by Center Director Vinayak Prasad, MD, MPH, cited the company’s choice…

Read more…

LEAVE A REPLY

Please enter your comment!
Please enter your name here